MX394513B - Anticuerpos de interferon beta y usos de los mismos - Google Patents

Anticuerpos de interferon beta y usos de los mismos

Info

Publication number
MX394513B
MX394513B MX2018013222A MX2018013222A MX394513B MX 394513 B MX394513 B MX 394513B MX 2018013222 A MX2018013222 A MX 2018013222A MX 2018013222 A MX2018013222 A MX 2018013222A MX 394513 B MX394513 B MX 394513B
Authority
MX
Mexico
Prior art keywords
interferon beta
beta antibodies
antibodies
antigen
binding fragments
Prior art date
Application number
MX2018013222A
Other languages
English (en)
Other versions
MX2018013222A (es
Inventor
Anthony John Coyle
Christine Huard
Edward Roland Lavallie
Eric M Bennett
James Perry Hall
Janet Elizabeth Buhlmann
Juan Carlos Almagro
Lidia Mosyak
Sreekumar R Kodangattil
Stefano V Gulla
Steven A Greenberg
Original Assignee
Pfizer
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Brigham & Womens Hospital Inc filed Critical Pfizer
Publication of MX2018013222A publication Critical patent/MX2018013222A/es
Publication of MX394513B publication Critical patent/MX394513B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a anticuerpos, o fragmentos de los mismos de enlace al antígeno, que de manera específica enlazan el interferón beta (IFNß); dichos anticuerpos, o fragmentos de los mismos de enlace al antígeno, son útiles para varios propósitos terapéuticos o de diagnóstico.
MX2018013222A 2016-04-29 2017-04-28 Anticuerpos de interferon beta y usos de los mismos MX394513B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662329327P 2016-04-29 2016-04-29
US201662339709P 2016-05-20 2016-05-20
US201762483669P 2017-04-10 2017-04-10
PCT/US2017/030089 WO2017189983A1 (en) 2016-04-29 2017-04-28 Interferon beta antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2018013222A MX2018013222A (es) 2019-04-22
MX394513B true MX394513B (es) 2025-03-24

Family

ID=59215947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013222A MX394513B (es) 2016-04-29 2017-04-28 Anticuerpos de interferon beta y usos de los mismos

Country Status (28)

Country Link
US (3) US10829553B2 (es)
EP (2) EP3448419B1 (es)
JP (2) JP6799076B2 (es)
KR (1) KR102527840B1 (es)
CN (1) CN109069606B (es)
AU (1) AU2017258492B2 (es)
CA (1) CA2965652A1 (es)
CO (1) CO2018012497A2 (es)
DK (1) DK3448419T5 (es)
ES (1) ES2950288T3 (es)
FI (1) FI3448419T3 (es)
HR (1) HRP20230605T1 (es)
HU (1) HUE063621T2 (es)
IL (1) IL262244B2 (es)
MX (1) MX394513B (es)
MY (1) MY194084A (es)
NZ (1) NZ747225A (es)
PE (1) PE20190371A1 (es)
PH (1) PH12018502275B1 (es)
PL (1) PL3448419T3 (es)
PT (1) PT3448419T (es)
RU (1) RU2750454C2 (es)
SA (1) SA518400327B1 (es)
SG (1) SG11201809456UA (es)
SI (1) SI3448419T1 (es)
TW (1) TWI776808B (es)
WO (1) WO2017189983A1 (es)
ZA (1) ZA201806682B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102527840B1 (ko) 2016-04-29 2023-05-03 화이자 인코포레이티드 인터페론 베타 항체 및 그의 용도
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
JP7386877B2 (ja) 2019-01-31 2023-11-27 イミューンセント バイオテクノロジー,インコーポレイテッド 新規の抗ifnar1抗体
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US20250002599A1 (en) * 2021-09-03 2025-01-02 Novarock Biotherapeutics, Ltd. Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof
CN114733455B (zh) * 2022-04-15 2023-02-14 北京田园奥瑞生物科技有限公司 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法
EP4590699A1 (en) * 2022-09-22 2025-07-30 Pfizer Inc. Methods of treatment with ifn-beta antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE68925365T2 (de) 1988-10-14 1996-09-12 Berlex Lab PEPTIDE, DIE EPITOPE AUF R-IFN-BETA REPRÄSENTIEREN, ANTIKöRPER DAGEGEN, UND IHRE ANWENDUNG
US6682896B1 (en) * 1988-10-14 2004-01-27 Schering Aktiengesellschaft Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL108584A (en) 1994-02-07 2008-03-20 Yeda Res & Dev Cloning of interferon -alpha/beta binding protein
ZA9811070B (en) * 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
CN102898521A (zh) * 2011-07-26 2013-01-30 上海市免疫学研究所 抗β-干扰素单克隆抗体及其应用
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
HK1254030A1 (zh) * 2015-06-26 2019-07-12 比奥贝拉蒂美国公司 治疗自身免疫病症和同种免疫病症的方法
KR102527840B1 (ko) 2016-04-29 2023-05-03 화이자 인코포레이티드 인터페론 베타 항체 및 그의 용도

Also Published As

Publication number Publication date
CN109069606B (zh) 2022-07-01
JP2019516366A (ja) 2019-06-20
JP2021040642A (ja) 2021-03-18
IL262244B1 (en) 2023-09-01
MX2018013222A (es) 2019-04-22
HUE063621T2 (hu) 2024-01-28
RU2750454C2 (ru) 2021-06-28
TW201739764A (zh) 2017-11-16
DK3448419T5 (da) 2024-09-09
US20210163588A1 (en) 2021-06-03
SG11201809456UA (en) 2018-11-29
HRP20230605T1 (hr) 2023-09-29
AU2017258492A1 (en) 2018-10-25
US20240174742A1 (en) 2024-05-30
JP7102489B2 (ja) 2022-07-19
PH12018502275A1 (en) 2019-09-09
EP4273165A3 (en) 2023-12-20
JP6799076B2 (ja) 2020-12-09
IL262244A (en) 2018-11-29
ZA201806682B (en) 2022-05-25
CO2018012497A2 (es) 2018-12-14
CA2965652A1 (en) 2017-10-29
US10829553B2 (en) 2020-11-10
EP3448419B1 (en) 2023-06-07
PE20190371A1 (es) 2019-03-08
EP3448419A1 (en) 2019-03-06
AU2017258492B2 (en) 2023-12-07
EP4273165A2 (en) 2023-11-08
PH12018502275B1 (en) 2024-06-28
PL3448419T3 (pl) 2023-09-04
WO2017189983A1 (en) 2017-11-02
SI3448419T1 (sl) 2023-10-30
DK3448419T3 (da) 2023-06-26
CN109069606A (zh) 2018-12-21
TWI776808B (zh) 2022-09-11
FI3448419T3 (fi) 2023-08-02
NZ747225A (en) 2022-07-29
IL262244B2 (en) 2024-01-01
US11858986B2 (en) 2024-01-02
BR112018072118A2 (pt) 2019-03-19
PT3448419T (pt) 2023-07-26
RU2018141839A (ru) 2020-05-29
ES2950288T3 (es) 2023-10-06
US12448439B2 (en) 2025-10-21
MY194084A (en) 2022-11-11
US20170313769A1 (en) 2017-11-02
RU2018141839A3 (es) 2020-10-16
KR102527840B1 (ko) 2023-05-03
SA518400327B1 (ar) 2022-12-03
KR20190003625A (ko) 2019-01-09

Similar Documents

Publication Publication Date Title
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12017502180A1 (en) Tau-binding antibodies
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12017500890A1 (en) Antibody drug conjugates
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MY193677A (en) Tau-binding antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
PH12019502694A1 (en) Anti-trkb antibodies
WO2017049038A3 (en) Anti-cd115 antibodies
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
WO2016135462A8 (en) Treatment
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.